selected publications
-
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
Science signaling.
2018
Academic Article
GET IT
Times cited: 43 -
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.
Cancer cell.
2018
Academic Article
GET IT
Times cited: 465 -
Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
2018
Academic Article
GET IT
Times cited: 12 -
Genome doubling shapes the evolution and prognosis of advanced cancers.
Nature genetics.
2018
Academic Article
GET IT
Times cited: 268 -
KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function.
Oncogene.
2018
Academic Article
GET IT
Times cited: 72 -
Accelerating Discovery of Functional Mutant Alleles in Cancer.
Cancer discovery.
2017
Academic Article
GET IT
Times cited: 191 -
Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
Nature medicine.
2017
Academic Article
GET IT
Times cited: 30 -
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
Nature medicine.
2017
Academic Article
GET IT
Times cited: 1922 -
Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA.
Journal of oncology.
2017
Review
GET IT
Times cited: 293 -
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.
Investigational new drugs.
2017
Academic Article
GET IT
Times cited: 10 -
Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay.
The Journal of molecular diagnostics : JMD.
2016
Academic Article
GET IT
Times cited: 77 -
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.
Cancer discovery.
2016
Academic Article
GET IT
Times cited: 222 -
Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.
Cancer discovery.
2016
Academic Article
GET IT
Times cited: 87 -
PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition.
Cancer cell.
2016
Academic Article
GET IT
Times cited: 146 -
Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups.
Blood cancer journal.
2014
Academic Article
GET IT
Times cited: 16